Cargando…

Guanidines: Synthesis of Novel Histamine H(3)R Antagonists with Additional Breast Anticancer Activity and Cholinesterases Inhibitory Effect

This study examines the properties of novel guanidines, designed and synthesized as histamine H(3)R antagonists/inverse agonists with additional pharmacological targets. We evaluated their potential against two targets viz., inhibition of MDA-MB-231, and MCF-7 breast cancer cells viability and inhib...

Descripción completa

Detalles Bibliográficos
Autores principales: Staszewski, Marek, Iwan, Magdalena, Werner, Tobias, Bajda, Marek, Godyń, Justyna, Latacz, Gniewomir, Korga-Plewko, Agnieszka, Kubik, Joanna, Szałaj, Natalia, Stark, Holger, Malawska, Barbara, Więckowska, Anna, Walczyński, Krzysztof
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10223552/
https://www.ncbi.nlm.nih.gov/pubmed/37242458
http://dx.doi.org/10.3390/ph16050675
Descripción
Sumario:This study examines the properties of novel guanidines, designed and synthesized as histamine H(3)R antagonists/inverse agonists with additional pharmacological targets. We evaluated their potential against two targets viz., inhibition of MDA-MB-231, and MCF-7 breast cancer cells viability and inhibition of AChE/BuChE. ADS10310 showed micromolar cytotoxicity against breast cancer cells, combined with nanomolar affinity at hH(3)R, and may represent a promising target for the development of an alternative method of cancer therapy. Some of the newly synthesized compounds showed moderate inhibition of BuChE in the single-digit micromolar concentration ranges. H(3)R antagonist with additional AChE/BuChE inhibitory effect might improve cognitive functions in Alzheimer’s disease. For ADS10310, several in vitro ADME-Tox parameters were evaluated and indicated that it is a metabolically stable compound with weak hepatotoxic activity and can be accepted for further studies.